Efficacy and safety of laxatives for chronic constipation in long‐term care settings: A systematic review

Alsalimy, Noor; Madi, Lama; Awaisu, Ahmed

doi:10.1111/jcpt.12721

Cited by 56 publications

(38 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Docusate is commonly prescribed, but there is no evidence that it is effective. 106 Bulking agents with adequate fluid intake, osmotic agents, and direct colonic muscle stimulants such as Senna and bisacodyl for narcotic-induced constipation should be considered. If the patient has a fecal impaction on rectal examination, suppositories or enemas are appropriate.…”

Section: Caring For Hip Fracture Patients In the Pac Facilitymentioning

confidence: 99%

Postacute Management of Older Adults Suffering an Osteoporotic Hip Fracture: A Consensus Statement From the International Geriatric Fracture Society

Reyes

Mendelson

Mujahid

et al. 2020

Geriatr Orthop Surg Rehabil

View full text Add to dashboard Cite

Background: The majority of patients require postacute care (PAC) after a hip fracture. Despite its importance, there is no established consensus regarding the standards of care provided to hip fracture patients in PAC facilities. Methodology: A writing group was created by professionals from the International Geriatric Fracture Society (IGFS) with representation from other organizations. The focus of the statements included in this article is toward PAC providers located in nursing facilities. Contributions were integrated in a single document that underwent several reviews by each author and then underwent a final review by the lead and senior authors. After this process was completed, the document was appraised by reviewers from IGFS. Results/Conclusion: A total of 15 statements were crafted. These statements summarize the best available evidence and is intended to help PAC facilities managing older adults with hip fractures more efficiently, aiming toward overall better outcomes in the areas of function, quality of life, and with less complications that could interfere with their optimal recovery.

show abstract

Section: Caring For Hip Fracture Patients In the Pac Facilitymentioning

confidence: 99%

Postacute Management of Older Adults Suffering an Osteoporotic Hip Fracture: A Consensus Statement From the International Geriatric Fracture Society

Reyes

Mendelson

Mujahid

et al. 2020

Geriatr Orthop Surg Rehabil

View full text Add to dashboard Cite

show abstract

“…Although laxatives are effective, some patients could experience adverse drug reactions. [2] Constipation is one of the most common GI motility…”

Section: Introductionmentioning

confidence: 99%

“…Traditional medications, including bulk forming laxatives, osmotic laxatives, and stool softeners, have been used to treat GI motility disorders. Although laxatives are effective, some patients could experience adverse drug reactions 2 . Constipation is one of the most common GI motility disorders in Western countries 3 .…”

mentioning

confidence: 99%

YH12852, a Potent and Selective Receptor Agonist of 5‐hydroxytryptamine, Increased Gastrointestinal Motility in Healthy Volunteers and Patients With Functional Constipation

Lee

Moon

Yoo

et al. 2020

Clinical Translational Sci

View full text Add to dashboard Cite

Gastrointestinal (GI) motility disorders are common, decreases quality of life, and imposes a substantial economic burden. YH12852 is a novel agonist of 5‐hydroxytryptamine for the treatment of GI motility disorders. This phase I/IIa study assessed the tolerability, pharmacodynamic (PD) and pharmacokinetic (PK) profiles of YH12852. In the multiple dose (MD) cohort, healthy subjects and patients with functional constipation were randomized and received orally YH12852 at 0.3, 0.5, 1, 2, or 3 mg or prucalopride 2 mg or their matching placebo, once daily for 14 days after breakfast. In the multiple low‐dose cohort (MLD), healthy subjects randomly received once‐daily oral doses of YH12852 at 0.05 or 0.1 mg for 14 days after breakfast. Questionnaires, gastric emptying breath test for PDs, and plasma samples for PKs were collected. In the MD cohort, a total of 56 subjects (29 healthy volunteers and 27 patients with functional constipation) were randomized, of whom 48 completed the study. In the MLD cohort, a total of 16 healthy subjects were randomized, and 15 subjects completed the study. YH12852 increased the average weekly frequency of spontaneous bowel movements and loosened the stool. In addition, YH12852 increased quality of life satisfaction, and decreased severity of constipation symptom and GI symptoms. YH12852 was safe and well‐tolerated up to 3 mg and showed nearly dose proportional PKs. In conclusion, YH12852 was safe and enhanced GI motility. YH12852 can be developed as an effective treatment option for GI motility disorders, including functional constipation. Further studies are warranted to confirm this possibility.

show abstract

“…Senna is a stimulant laxative, increases colon peristalsis, and stimulates liquid and electrolyte excretion in both colon and small intestine. Data about the use of senna in functional constipation is restricted (7)(8)(9)(10). Trimebutine is an efficacious drug in both hyper or hypomotility of the gastrointestinal system (GIS).…”

Section: Introductionmentioning

confidence: 99%

Çocukluk Çağında Fonksiyonel Kabızlık Tedavisi: Senna, Trimebutin ve Laktülozun Karşılaştırılması

Demir¹,

Kuloğlu²,

Kansu³

2020

Turkish Journal of Pediatric Disease

View full text Add to dashboard Cite

Objective: Data for the drugs used in maintenance therapy of functional constipation is limited in childhood. We aimed to evaluate the efficacy of senna, trimebutine, and lactulose in children with functional constipation (FC) or functional fecal incontinence (FFI).Material and Methods: Patients (2-18 years old) diagnosed as FC or FFI according to Rome III criteria who were treated with lactulose (n=36), senna (n=29), and trimebutine (n=33)were included. Patients completed a 0-5 Likert scale questionnaire about their symptoms. Stool consistency was evaluated by the Bristol Stool Chart. Compliance and tolerance to treatment and side effects were recorded. Clinical improvement and pharmacoeconomic evaluation were performed.Results: Clinical improvement in the senna group was significantly higher (p=0.036). Senna showed the highest improvement in stool consistency (p<0.001) and decreased fecal incontinence (p=0.039). Abdominal distention, abdominal pain, nausea/vomiting, and anal fissure were improved by trimebutine (p<0.05). Both senna and trimebutine decreased painful defecation and stool withholding. Lactulose improved anorexia and anal fissure. Senna was the most cost-effective drug. Conclusion:Treatment options for constipation should be tailored according to the predominant symptom. Lactulose may be recommended as the initial treatment for children with anorexia or anal fissure, trimebutine for abdominal distention, abdominal pain, nausea/vomiting, or anal fissure, respectively. Senna may be prescribed for the cost-effectiveness with high clinical improvement and less unpleasant taste.

show abstract

Efficacy and safety of laxatives for chronic constipation in long‐term care settings: A systematic review

Cited by 56 publications

References 38 publications

Postacute Management of Older Adults Suffering an Osteoporotic Hip Fracture: A Consensus Statement From the International Geriatric Fracture Society

Postacute Management of Older Adults Suffering an Osteoporotic Hip Fracture: A Consensus Statement From the International Geriatric Fracture Society

YH12852, a Potent and Selective Receptor Agonist of 5‐hydroxytryptamine, Increased Gastrointestinal Motility in Healthy Volunteers and Patients With Functional Constipation

Çocukluk Çağında Fonksiyonel Kabızlık Tedavisi: Senna, Trimebutin ve Laktülozun Karşılaştırılması

Contact Info

Product

Resources

About